1. Tumor progression, metastasis, and modulators of epithelial–mesenchymal transition in endometrioid endometrial carcinoma: an update
    Annu Makker et al, 2016, Endocrine-Related Cancer CrossRef
  2. Medroxyprogesterone acetate inhibits wound closure of human endometrial epithelial cells and stromal fibroblasts in vitro
    Mickey V. Patel et al, 2021, Scientific Reports CrossRef
  3. Overexpression of TICRR and PPIF confer poor prognosis in endometrial cancer identified by gene co-expression network analysis
    Linlin Yang et al, 2021, Aging CrossRef
  4. CCL20 mediates RANK/RANKL-induced epithelial-mesenchymal transition in endometrial cancer cells
    Yao Liu et al, 2016, Oncotarget CrossRef
  5. Capecitabine inhibits epithelial‑to‑mesenchymal transition and proliferation of colorectal cancer cells by mediating the RANK/RANKL pathway
    Minghai Shao et al, 2022, Oncology Letters CrossRef
  6. Aberrant upregulation of CDK1 contributes to medroxyprogesterone acetate (MPA) resistance in cancer-associated fibroblasts of the endometrium
    Intan Sofia Omar et al, 2022, Biochemical and Biophysical Research Communications CrossRef
  7. Targeting the RANKL/RANK/OPG Axis for Cancer Therapy
    Jie Ming et al, 2020, Frontiers in Oncology CrossRef
  8. Adipocytokines and disease progression in endometrial cancer: a systematic review
    Irene Ray et al, 2022, Cancer and Metastasis Reviews CrossRef
  9. The Non-Bone-Related Role of RANK/RANKL Signaling in Cancer
    Peter A. van Dam et al, 2020, Tumor Microenvironment CrossRef

  10. Identification and Validation of MSX1 as a Key Candidate for Progestin Resistance in Endometrial Cancer


    Linlin Yang et al, 2020, OncoTargets and Therapy CrossRef
  11. RANK–RANKL signalling in cancer
    Nathalie Renema et al, 2016, Bioscience Reports CrossRef
  12. Siegesbeckia orientalis Extract Inhibits TGFβ1-Induced Migration and Invasion of Endometrial Cancer Cells
    Chi-Chang Chang et al, 2016, Molecules CrossRef
  13. RANK/RANKL signaling inhibition may improve the effectiveness of checkpoint blockade in cancer treatment
    Peter A. van Dam et al, 2019, Critical Reviews in Oncology/Hematology CrossRef
  14. Receptor Activator of Nuclear Factor Kappa B (RANK) and Clinicopathological Variables in Endometrial Cancer: A Study at Protein and Gene Level
    Raúl Gómez et al, 2018, International Journal of Molecular Sciences CrossRef
  15. Cyclopropanyldehydrocostunolide LJ attenuates high glucose-induced podocyte injury by suppressing RANKL/RANK-mediated NF-κB and MAPK signaling pathways
    Xiao-Wen Chen et al, 2016, Journal of Diabetes and its Complications CrossRef
  16. Medroxyprogesterone acetate causes the alterations of endoplasmic reticulum related mRNAs and lncRNAs in endometrial cancer cells
    Wenjiao Cao et al, 2019, BMC Medical Genomics CrossRef
  17. Clinical prognostic significance and pro-metastatic activity of RANK/RANKL via the AKT pathway in endometrial cancer
    Jing Wang et al, 2016, Oncotarget CrossRef
  18. TRPS1 regulates the opposite effect of progesterone via RANKL in endometrial carcinoma and breast carcinoma
    Linlin Yang et al, 2023, Cell Death Discovery CrossRef
  19. Advances in the molecular mechanisms underlying progestin resistance in endometrial cancer
    Jie Liu et al, 2023, Fundamental Research CrossRef
  20. Differential expression of receptor activator of nuclear factor kappa B in healthy endometrium, ovarian endometrioma, and endometrioid ovarian cancer
    Eulàlia Gregori et al, 2020, American Journal of Obstetrics and Gynecology CrossRef
  21. Identification of an immune gene signature for predicting the prognosis of patients with uterine corpus endometrial carcinoma
    Cankun Zhou et al, 2020, Cancer Cell International CrossRef